Clinical Trial Update: Expanded Access for LJPC-501

View source ↗

Summary

La Jolla Pharmaceutical Company's LJPC-501 has been approved for marketing to treat catecholamine-resistant hypotension and distributive shock, including relate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Distributive Shock
• High-output Shock
• Hypotension
• Sepsis
• Vasodilatory Shock

Drugs mentioned

• LJPC-501

Snippet

Sponsor: La Jolla Pharmaceutical Company | Conditions: Catecholamine Resistant Hypotension (CRH), Distributive Shock | Status: APPROVED_FOR_MARKETING